Pyramid Analytics Named Finalist for 2022 Ventana Research Digital Innovation Awards
23.6.2022 15:00:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced that the company has been selected as a finalist in the 15th Annual Ventana Research Digital Innovation Awards. The company’s Pyramid Decision Intelligence Platform is among just three finalists in the Analytics category. The Business Intelligence and Analytics segment of the global software market is highly competitive. There are an estimated 120 vendors in the space. Ventana Research will announce the winner on June 29, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005217/en/
Pyramid Analytics, a pioneering decision intelligence platform provider, is a finalist in the 15th Annual Ventana Research Digital Innovation Awards. The company’s Pyramid Decision Intelligence Platform is among just three finalists in the Analytics category. (Graphic: Business Wire)
Ventana Research Digital Innovation Awards identify the top technologies and products that have the most striking impact in their respective markets, recognizing pioneering vendors that contribute advancements in technology, drive change and increase value for organizations worldwide. This year’s finalists represent a significant wave of technological advancements in use of AI (artificial intelligence) and ML (machine learning) infused across tools and applications demonstrating substantive advancements, that from Ventana’s analysis, have the most significant impact to the technology industry.
Key Points:
- Pyramid Analytics is a finalist in the Analytics category of the 15th Annual Ventana Research Digital Innovation Awards for its ground-breaking Pyramid Decision Intelligence Platform.
- The Pyramid Decision Intelligence Platform is one of just three analytics products selected by Ventana Research analysts. Other finalists include industry veteran, Qlik.
- Ventana Research will announce the winner on June 29, 2022.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Mark Smith , CEO and Chief Research Officer at Ventana Research: “The importance of digital innovation in technology to the value of every organization is essential to be productive and resilient in the best and worst of times, and our 15 years in identifying and recognizing technology providers continues to be a long-standing tradition of our firm.
“Congratulations to the finalists of our 15th annual Ventana Research Digital Innovation Awards, for their diligence to excellence in technology and dedication to advance the technology industry to be impactful and prepare for the readiness required by every organization."
Omri Kohl , Chief Executive Officer and Co-Founder, Pyramid Analytics: “I am thrilled that Pyramid is a finalist in the Analytics category of the Ventana Research Digital Innovation Awards. The Analytics research team at Ventana – Mark Smith, Dave Menninger, and Matt Aslett – bring credibility, experience, and expertise to their coverage of Data & Analytics that is second to none. In addition, Ventana is widely regarded as emphatically objective in their research. Recognition from that team means a lot.
“Importantly, Ventana Research is among a growing group of industry advisors who see the innovation that the Pyramid Decision Intelligence Platform has brought to a BI and analytics that went unchanged for too long. Decision intelligence clearly is the future of analytics. We use AI to not just move from predictive to prescriptive analytics – no small feat – but to make the power of data-driven decisions available to anyone in an organization who makes them.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005217/en/
Contact information
UK
Susie Evershed
Resonance
+44 7966 145092
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom